^
Association details:
Biomarker:B2M mutation
Cancer:Hodgkin Lymphoma
Drug:Tyvyt (sintilimab) (PD1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab

Excerpt:
A total of 192 plasma samples from 75 patients with r/r cHL were collected at baseline and upon therapeutic evaluation...the mutations of B2M, TNFRSF14 and KDM2B were found to be associated with acquired resistance.
DOI:
10.1016/j.ebiom.2020.102731